IDEXX Laboratories Inc. (IDXX)
IDEXX was incorporated in Delaware in 1983 and develops, makes and distributes products and services mainly for the companion animal veterinary, livestock, poultry and dairy, and water testing industries, and also makes human medical point-of-care diagnostic products. Its main lines are point-of-care veterinary diagnostics covering instruments, consumables and rapid assay kits; veterinary reference laboratory and consulting services; practice management systems, software and imaging for veterinarians; health monitoring and laboratory instruments for biomedical research; products for livestock, poultry and dairy; and tests for microbiological contaminants in water. It reports three segments, Companion Animal Group, Water quality products and Livestock, Poultry and Dairy, with an Other operating segment holding the human medical diagnostics business and an out-licensing arrangement.
Compare with another name What $10,000 in IDEXX Laboratories became Open in your desk ↗
Latest results
this quarterthe same quarter a year earlierHover a bar for its figure.
this yearthe year beforeHover a bar for its figure.
The years before, in words
IDEXX Laboratories (IDXX) reported revenue of $4.3 billion for fiscal 2025, the year ended 31 December 2025, up 10.4% on the year before. Net income was $1.1 billion and diluted earnings per share $13.08. Revenue was $3.9 billion in fiscal 2024, $3.7 billion in fiscal 2023, $3.4 billion in fiscal 2022 and $3.2 billion in fiscal 2021. Net income in the same years was $888 million, $845 million, $679 million and $745 million. Over the twelve months to 30 September 2026, IDEXX Laboratories reported revenue of $4.7 billion and net income of $1.2 billion. Revenue grew 9.7% a year, compounded, over the five years to fiscal 2025. IDEXX Laboratories had 79 million shares outstanding at the latest filed count. At 30 September 2026 it carried $849 million of debt and $198 million of cash. At the close of 6 November 2026 the market cap of IDEXX Laboratories was $53.3 billion, 45.6 times its earnings over the last twelve months.Ratios
From the filings
ROE63.2%
ROCE55.4%
Operating margin32.3%
Net margin25.4%
FCF margin28.0%
Interest cover43.5x
Debt to equity0.45x
Cash conversion1.20x
Share count, last 12 months-1.5%
Sales CAGR, 3 years8.5%
Profit CAGR, 3 years16.0%
EPS, TTM$14.83
At the close of 6 November 2026
Price$675.90
Market cap$53.3 billion
Stock P/E45.6x
Price to book28.5x
EV / EBITDA32.4x
Dividend yieldn/a
Market cap / sales11.4x
52-week high$766.68
52-week low$504.70
Price, 1 year-5.3%
Price CAGR, 3 years17.0%
Price CAGR, 5 years1.2%
29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of IDEXX Laboratories Inc.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.IDXXgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.Quarterly results
| Q4 FY2021 * | Q1 FY2022 | Q2 FY2022 | Q3 FY2022 | Q4 FY2022 * | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 801 | 837 | 861 | 842 | 829 | 900 | 944 | 916 | 902 | 964 | 1,004 | 976 | 954 | 998 | 1,109 | 1,105 | 1,091 | 1,141 | 1,217 | 1,214 |
| Cost of revenue | 345 | 338 | 347 | 335 | 344 | 357 | 371 | 368 | 375 | 371 | 384 | 380 | 384 | 375 | 415 | 422 | 432 | 418 | 437 | 450 |
| Gross profit | 456 | 499 | 514 | 507 | 485 | 543 | 573 | 548 | 526 | 593 | 619 | 596 | 571 | 623 | 695 | 683 | 658 | 723 | 779 | 764 |
| Gross margin | 57% | 60% | 60% | 60% | 59% | 60% | 61% | 60% | 58% | 62% | 62% | 61% | 60% | 62% | 63% | 62% | 60% | 63% | 64% | 63% |
| R&D | 45.3 | 40.2 | 123 | 48.0 | 43.4 | 44.7 | 46.5 | 48.0 | 51.8 | 52.6 | 55.5 | 54.0 | 57.7 | 59.1 | 61.9 | 63.4 | 66.8 | 65.8 | 65.4 | 68.8 |
| Operating income | 199 | 248 | 179 | 245 | 227 | 280 | 296 | 275 | 245 | 299 | 264 | 304 | 262 | 317 | 373 | 355 | 316 | 363 | 426 | 402 |
| Operating margin | 25% | 30% | 21% | 29% | 27% | 31% | 31% | 30% | 27% | 31% | 26% | 31% | 27% | 32% | 34% | 32% | 29% | 32% | 35% | 33% |
| Interest expense | 7.5 | 7.0 | 8.3 | 11.0 | 13.5 | 13.1 | 10.5 | 8.6 | 9.3 | 7.9 | 8.1 | 7.7 | 7.5 | 7.7 | 11.3 | 10.7 | 9.2 | 7.7 | 10.2 | 7.5 |
| Pre-tax income | 192 | 241 | 171 | 234 | 213 | 268 | 286 | 268 | 240 | 295 | 259 | 299 | 256 | 310 | 362 | 345 | 307 | 355 | 417 | 399 |
| Tax rate | 15% | 20% | 23% | 23% | 19% | 20% | 22% | 21% | 19% | 20% | 22% | 22% | 16% | 22% | 19% | 20% | 19% | 22% | 19% | 21% |
| Net income | 163 | 194 | 132 | 181 | 172 | 214 | 224 | 212 | 195 | 236 | 203 | 233 | 216 | 243 | 294 | 275 | 248 | 278 | 338 | 317 |
| Net margin | 20% | 23% | 15% | 21% | 21% | 24% | 24% | 23% | 22% | 24% | 20% | 24% | 23% | 24% | 26% | 25% | 23% | 24% | 28% | 26% |
| Diluted EPS | $1.88 | $2.27 | $1.56 | $2.15 | $2.05 | $2.55 | $2.67 | $2.53 | $2.32 | $2.81 | $2.44 | $2.80 | $2.62 | $2.96 | $3.63 | $3.40 | $3.08 | $3.47 | $4.27 | $4.01 |
| Operating cash flow | 210 | 115 | 65.8 | 189 | 173 | 184 | 200 | 272 | 250 | 199 | 248 | 220 | 262 | 238 | 186 | 402 | 356 | 266 | 347 | 450 |
| Capital expenditure | 31.8 | 31.8 | 30.1 | 37.7 | 49.2 | 39.5 | 27.5 | 34.1 | 32.6 | 30.3 | 33.3 | 28.1 | 29.3 | 30.0 | 34.1 | 31.1 | 29.4 | 32.0 | 24.6 | 28.9 |
| Free cash flow | 178 | 82.9 | 35.8 | 151 | 124 | 144 | 173 | 238 | 217 | 168 | 215 | 192 | 233 | 208 | 152 | 371 | 326 | 234 | 323 | 421 |
| Buybacks | 245 | 266 | 307 | 173 | 74.0 | 0.0 | 0.0 | 35.1 | 36.9 | 155 | 216 | 221 | 246 | 401 | 338 | 240 | 238 | 351 | 347 | 112 |
| Shares outstanding | 85m | 84m | 83m | 83m | 83m | 83m | 83m | 83m | 83m | 83m | 82m | 82m | 82m | 81m | 80m | 80m | 80m | 79m | 79m | 79m |
| Filing | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Income statement (profit and loss)
Play it forward: change any box and its column follows; every box opens at the company's own record, shown under the row's name, and says when you set it outside every year in the table.
Read more
Each column runs from the last twelve months as filed to the year chosen in its heading, at a yearly rate. Sales growth starts at the company's own five-year rate and eases a third of the way each year toward the median of the 130 peers in Pharmaceutical Products (15.6% a year), because a rate far from the rest rarely lasts. Before you open a year, the strip reads today's price backwards: the yearly sales growth that brings EPS, at the company's own margins, tax and share count, to today's price at the median P/E of the 65 peers in Pharmaceutical Products (24.2). Low, middle, high opens three columns for one year: the low and high cases take the company's own weaker and stronger years in the table (the lower and upper quarter of its yearly sales growth and operating margin) and the lower and higher of today's P/E and its peers'; the middle is the boxes as they open. Net income keeps the share that went to minority holders; EPS is net income over the diluted shares, on the same basis as the EPS in the table. The price is that year's EPS at the P/E you set, and the yearly return runs from today's price to the year's end. These are your assumptions and your arithmetic, not an estimate of ours. The link carries your columns, so you can send the forecast to someone.| FY2008 | FY2009 | FY2010 | FY2011 † | FY2012 † | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,024 | 1,032 | 1,103 | 1,219 | 1,293 | 1,377 | 1,486 | 1,602 | 1,775 | 1,969 | 2,213 | 2,407 | 2,707 | 3,215 | 3,367 | 3,661 | 3,898 | 4,304 | 4,662 |
| Cost of revenue | 494 | 505 | 525 | 572 | 594 | 621 | 670 | 712 | 800 | 872 | 972 | 1,041 | 1,136 | 1,326 | 1,363 | 1,471 | 1,519 | 1,644 | 1,738 |
| Gross profit | 530 | 526 | 579 | 647 | 699 | 756 | 816 | 890 | 975 | 1,097 | 1,242 | 1,366 | 1,571 | 1,889 | 2,004 | 2,190 | 2,379 | 2,660 | 2,924 |
| Gross margin | 51.7% | 51.0% | 52.4% | 53.0% | 54.1% | 54.9% | 54.9% | 55.6% | 54.9% | 55.7% | 56.1% | 56.7% | 58.0% | 58.8% | 59.5% | 59.8% | 61.0% | 61.8% | 62.7% |
| Research and development | 70.7 | 65.1 | 68.6 | 76.0 | 82.0 | 88.0 | 98.3 | 99.7 | 101 | 109 | 118 | 133 | 141 | 161 | 255 | 191 | 220 | 251 | 267 |
| Operating income | 172 | 176 | 204 | 236 | 263 | 267 | 260 | 300 | 350 | 413 | 491 | 553 | 695 | 932 | 899 | 1,097 | 1,128 | 1,360 | 1,506 |
| Operating margin | 16.8% | 17.1% | 18.5% | 19.4% | 20.3% | 19.4% | 17.5% | 18.7% | 19.7% | 21.0% | 22.2% | 23.0% | 25.7% | 29.0% | 26.7% | 30.0% | 29.0% | 31.6% | 32.3% |
| Interest expense | 4.6 | 1.9 | 2.4 | 3.5 | 3.8 | 5.4 | 15.4 | 29.2 | 32.0 | 37.2 | 34.7 | 31.1 | 33.1 | 29.8 | 39.9 | 41.6 | 31.2 | 38.9 | 34.6 |
| Pre-tax income | 170 | 175 | 202 | 234 | 261 | 263 | 247 | 273 | 322 | 381 | 458 | 522 | 662 | 903 | 860 | 1,061 | 1,110 | 1,324 | 1,479 |
| Income tax | 54.0 | 52.3 | 60.8 | 72.7 | 82.3 | 75.5 | 64.6 | 81.0 | 99.8 | 118 | 80.7 | 94.4 | 79.9 | 158 | 181 | 216 | 222 | 265 | 297 |
| Effective tax rate | 31.7% | 30.0% | 30.1% | 31.0% | 31.6% | 28.7% | 26.2% | 29.7% | 31.0% | 30.9% | 17.6% | 18.1% | 12.1% | 17.5% | 21.0% | 20.4% | 20.0% | 20.0% | 20.1% |
| Net income | 116 | 122 | 141 | 162 | 178 | 188 | 182 | 192 | 222 | 263 | 377 | 428 | 582 | 745 | 679 | 845 | 888 | 1,059 | 1,182 |
| Net margin | 11.3% | 11.8% | 12.8% | 13.3% | 13.8% | 13.6% | 12.2% | 12.0% | 12.5% | 13.4% | 17.0% | 17.8% | 21.5% | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% | 25.4% |
| Diluted EPS | $0.94 | $1.00 | $1.19 | $1.39 | $1.58 | $1.74 | $1.79 | $2.05 | $2.44 | $2.94 | $4.26 | $4.89 | $6.71 | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 | $14.83 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
From each year's 10-K, linked; TTM is the last four quarters.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.Revenue by segment FY2009 to FY2025
| FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAG | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2,119 | 2,386 | 2,890 | 3,059 | 3,352 | 3,574 | 3,953 | 92.2% |
| Water segment revenue | 73.2 | 76.5 | 82.1 | 84.7 | 88.0 | 94.7 | 96.9 | 104 | 114 | 125 | 133 | 129 | 147 | 156 | 168 | 185 | 201 | 4.7% |
| LPD | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 133 | 146 | 136 | 123 | 122 | 122 | 132 | 3.1% |
| CAG segment revenue | n/a | 906 | 1,000 | 1,072 | 1,140 | 1,223 | 1,356 | 1,523 | 1,703 | 1,935 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| CAG/LPD Segment Transition | n/a | n/a | n/a | n/a | 9.9 | 13.8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Companion Animal Group | 843 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| LPD segment revenue | n/a | 81.2 | 114 | 111 | 124 | 141 | 127 | 126 | 128 | 131 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Livestock And Poultry Diagnostics Segment Revenue | 77.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other segment revenue | 37.9 | 40.0 | 23.3 | 25.1 | 25.1 | 26.8 | 21.6 | 22.7 | 22.8 | 22.0 | 22.2 | 46.4 | 43.0 | n/a | n/a | n/a | n/a | n/a |
CAG FY2019 to FY2025Water segment revenueLPD FY2019 to FY2025Other segment revenue FY2009 to FY2021CAG segment revenue FY2010 to FY2018LPD segment revenue FY2010 to FY2018CAG/LPD Segment Transition FY2013 to FY2014Companion Animal Group FY2009Livestock And Poultry Diagnostics Segment Revenue FY2009
$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.Profit by segment FY2022 to FY2025
The gross profit each segment reports. Costs IDEXX Laboratories does not charge to a segment are left out, so the segments can add up to more than the company's own gross profit.
| FY2022 | FY2023 | FY2024 | FY2025 | Margin FY2025 | |
|---|---|---|---|---|---|
| CAG | 1,807 | 2,002 | 2,179 | 2,449 | 61.9% |
| Water segment revenue | 110 | 116 | 130 | 139 | 69.2% |
| LPD | 73.0 | 65.4 | 62.6 | 64.2 | 48.7% |
CAGWater segment revenueLPD
$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.
FY2025Share of salesShare of profit
CAG92%92%
Water segment revenue5%5%
LPD3%2%
Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has a gross profit figure. A margin is a segment's gross profit over its own sales.Revenue by product or service FY2016 to FY2025
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | 1,071 | 1,176 | 1,323 | 1,423 | 1,587 | 1,875 | 1,929 | 2,090 | 2,248 | 2,539 | 59.0% |
| Service revenue | 704 | 793 | 891 | 984 | 1,120 | 1,340 | 1,439 | 1,571 | 1,649 | 1,764 | 41.0% |
Product revenueService revenue
$ million; hover a block for its figure and share
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.Revenue by region FY2019 to FY2025
| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|
| United States | 1,496 | 1,691 | 1,996 | 2,183 | 2,391 | 2,533 | 2,753 | 64.0% |
| Other | 122 | 148 | 168 | 162 | 176 | 196 | 230 | 5.3% |
| Germany | 104 | 119 | 147 | 138 | 150 | 174 | 207 | 4.8% |
| Canada | 99.5 | 107 | 140 | 143 | 150 | 153 | 167 | 3.9% |
| United Kingdom | 91.0 | 90.2 | 115 | 110 | 122 | 135 | 154 | 3.6% |
| France | 64.8 | 74.8 | 90.8 | 84.5 | 96.8 | 111 | 126 | 2.9% |
| Other | n/a | n/a | n/a | 96.3 | 104 | 110 | 124 | 2.9% |
| Australia | 71.1 | 79.6 | 94.4 | 96.4 | 95.5 | 102 | 112 | 2.6% |
| Latin America & Caribbean | 56.5 | 51.9 | 66.6 | 75.0 | 83.9 | 83.7 | 90.4 | 2.1% |
| Japan | 67.2 | 74.7 | 84.3 | 77.7 | 75.6 | 73.1 | 83.4 | 1.9% |
| Spain | 36.4 | 39.3 | 48.2 | 47.0 | 52.3 | 61.9 | 71.0 | 1.6% |
| Italy | 39.7 | 42.8 | 52.1 | 48.2 | 53.8 | 58.2 | 66.9 | 1.6% |
| Switzerland | 20.9 | 24.9 | 32.0 | 30.6 | 34.8 | 37.2 | 41.7 | 1.0% |
| Netherlands | 19.4 | 23.5 | 29.7 | 26.9 | 30.5 | 34.0 | 40.5 | 0.9% |
| China | 57.5 | 70.8 | 63.2 | 49.2 | 44.2 | 35.8 | 36.0 | 0.8% |
| Other | 61.1 | 68.2 | 89.5 | n/a | n/a | n/a | n/a | n/a |
United StatesOtherGermanyCanadaUnited KingdomFranceOther FY2022 to FY2025Other FY2019 to FY2021Other
$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.First forecast against the result
IDEXX Laboratories's EPS landed at or above the top of the range in 4 and under it in 1 of the 5 years shown (FY2018 to FY2025).
- At or above the top of the range
- Inside the range
- Under the range
Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.
| Fiscal year | First forecast EPS | Result |
|---|---|---|
| FY2018 | $4.04 to $4.18 | $4.26 |
| FY2021 | $7.39 to $7.71 | $8.60 |
| FY2023 | $9.27 to $9.75 | $10.06 |
| FY2024 | $10.84 to $11.33 | $10.67 |
| FY2025 | $11.74 to $12.24 | $13.08 |
- FY2026 forecast
- EPS $14.29 to $14.80, given 2 February 2026. Its result comes with the fourth-quarter results for FY2026.
- First forecast
- The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
- Result
- The figure the company reported for that year with its next fourth-quarter results.
- Years left out
- Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.
Cash flow
Follow the cash: free cash flow, which is operating cash flow less capital expenditure and share-based pay, for five years and after, in today's money.
Read more
The figure a share at the top is what a discounted cash flow calls intrinsic value, worked out on your assumptions. Everything after year five is one sum: the sixth year's cash, growing at the long-run rate every year after, added up and brought back to today's money. Each year runs from the last twelve months as filed. Sales growth opens where Play it forward does: the company's own five-year rate, easing a third of the way each year toward the median of the 130 peers in Pharmaceutical Products (15.6% a year); change a year and the years after it follow. Operating cash flow, capital expenditure and share-based pay open at the company's own median share of sales over its last five years, shown under each row. Share-based pay is taken off because operating cash flow adds back the shares paid to staff as if they cost nothing; set it to 0 to leave it in. Capital spending counts every capital line the company files in its cash flow, such as equipment it leases to customers, software, wells or property it develops, named under the row, while the Capital expenditure row in the table below stays the one line as filed; buying a business, securities or a finished property is not counted. The discount rate opens at 10%, about what US stocks have returned a year over the long run, so it is the return you give up by holding this company instead of the market; the growth after year five opens at 3%, a little under the US economy's long-run growth in dollars, because no company outgrows it for ever. Net debt is the debt and short-term borrowings less the cash on the latest balance sheet that shows the debt; the figure per share divides what is left by the diluted share count. These are your assumptions and your arithmetic, not an estimate of ours. The link carries them, so you can send them to someone.| FY2008 | FY2009 | FY2010 | FY2011 † | FY2012 † | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 143 | 175 | 179 | 218 | 222 | 246 | 236 | n/a | 339 | 373 | 400 | 459 | 648 | 756 | 543 | 907 | 929 | 1,182 | 1,419 |
| Capital expenditure | 90.0 | 50.7 | 38.9 | 49.7 | 57.6 | 77.6 | 60.5 | 82.9 | 64.8 | 74.4 | 116 | 155 | 107 | 120 | 149 | 134 | 121 | 125 | 115 |
| Free cash flow | 53.3 | 124 | 140 | 168 | 165 | 168 | 175 | n/a | 274 | 299 | 284 | 304 | 541 | 636 | 394 | 773 | 808 | 1,057 | 1,304 |
| Free cash flow margin | 5.2% | 12.0% | 12.7% | 13.8% | 12.7% | 12.2% | 11.8% | n/a | 15.4% | 15.2% | 12.8% | 12.6% | 20.0% | 19.8% | 11.7% | 21.1% | 20.7% | 24.6% | 28.0% |
| Cash from investing | -91.6 | -53.6 | -43.2 | -94.2 | -58.1 | -86.1 | -80.4 | n/a | n/a | -139 | 139 | -206 | -109 | -293 | -195 | -125 | -207 | -136 | -335 |
| Cash from financing | -30.8 | -95.3 | -86.8 | -97.7 | -125 | -102 | -103 | n/a | n/a | -208 | -598 | -286 | -248 | -697 | -371 | -442 | -878 | -1,165 | -1,093 |
| Depreciation and amortisation | 48.0 | 49.8 | 46.0 | 48.2 | 52.4 | 54.6 | 58.9 | 69.0 | 78.2 | 83.1 | 83.2 | 88.0 | 96.0 | 105 | 112 | 115 | 130 | 145 | 158 |
| Share-based compensation | 10.5 | 11.6 | 13.3 | 15.5 | 16.0 | 16.5 | 18.1 | 19.9 | 19.9 | 23.5 | 25.2 | 39.3 | 31.0 | 37.8 | 49.8 | 59.7 | 60.3 | 60.0 | 64.7 |
| Buybacks | 132 | 83.1 | 143 | 256 | 132 | 368 | 618 | 402 | 304 | 283 | 369 | 302 | 183 | 747 | 820 | 71.9 | 837 | 1,217 | 1,048 |
| Diluted shares, weighted | 124m | 121m | 119m | 116m | 112m | 108m | 102m | 94m | 91m | 90m | 88m | 88m | 87m | 87m | 85m | 84m | 83m | 81m | 79m |
| Shares outstanding at period end | n/a | n/a | n/a | n/a | n/a | n/a | 95m | n/a | n/a | 87m | 86m | 85m | 85m | 85m | 83m | 83m | 82m | 80m | 79m |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Cash paid in the year, from the cash flow statement.
Read more
The dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.Balance sheet
| FY2008 | FY2009 | FY2010 | FY2011 † | FY2012 † | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Funded by | |||||||||||||||||||
| Shareholders' equity | 438 | 515 | 574 | 540 | 636 | 518 | 118 | -84.1 | -108 | -54.1 | -9.5 | 177 | 632 | 690 | 609 | 1,485 | 1,595 | 1,605 | 1,869 |
| Non-controlling interest | n/a | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.3 | 0.3 | 0.4 | 0.7 | 0.0 | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | 133 | 246 | 215 | 428 | 899 | 1,170 | 1,204 | 1,261 | 1,000 | 988 | 909 | 924 | 1,348 | 948 | 868 | 848 | 849 |
| Operating lease liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.0 | 67.5 | 77.0 | 87.4 | 101 | 99.7 | 97.8 | 101 | 97.5 |
| Other liabilities | n/a | 294 | 190 | 245 | 253 | 284 | 368 | 389 | 435 | 506 | 546 | 600 | 676 | 736 | 688 | 728 | 733 | 796 | 892 |
| Total liabilities and equity | n/a | 809 | 897 | 1,031 | 1,104 | 1,231 | 1,384 | 1,475 | 1,531 | 1,713 | 1,537 | 1,832 | 2,295 | 2,437 | 2,747 | 3,260 | 3,293 | 3,351 | 3,707 |
| Owned | |||||||||||||||||||
| Fixed assets | n/a | 200 | 202 | 217 | 245 | 281 | 304 | 333 | 357 | 379 | 437 | 534 | 555 | 588 | 649 | 702 | 713 | 747 | 732 |
| Goodwill | 139 | 149 | 149 | 173 | 175 | 181 | 184 | 179 | 178 | 200 | 214 | 240 | 243 | 359 | 362 | 366 | 405 | 414 | 641 |
| Intangible assets | n/a | 63.9 | 55.8 | 69.2 | 62.8 | 58.8 | 65.1 | 55.9 | 46.2 | 43.8 | 41.8 | 58.5 | 52.5 | 99.0 | 97.7 | 84.5 | 112 | 110 | 118 |
| Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 214 | 237 | 284 | 0.0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cash and equivalents | 78.9 | 107 | 157 | 184 | 224 | 279 | 323 | 129 | 155 | 188 | 124 | 90.3 | 384 | 144 | 113 | 454 | 288 | 180 | 198 |
| Receivables | n/a | 115 | 120 | 141 | 138 | 158 | 152 | 188 | 204 | 235 | 249 | 269 | 331 | 368 | 401 | 457 | 474 | 552 | 616 |
| Inventory | n/a | 110 | 128 | 133 | 141 | 133 | 160 | 189 | 158 | 164 | 173 | 195 | 210 | 269 | 368 | 380 | 382 | 378 | 391 |
| Other assets | n/a | 63.7 | 85.7 | 114 | 117 | 139 | 196 | 187 | 195 | 220 | 298 | 446 | 518 | 609 | 757 | 816 | 920 | 969 | 1,012 |
| Total assets | n/a | 809 | 897 | 1,031 | 1,104 | 1,231 | 1,384 | 1,475 | 1,531 | 1,713 | 1,537 | 1,832 | 2,295 | 2,437 | 2,747 | 3,260 | 3,293 | 3,351 | 3,707 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
At the fiscal year end; the TTM column is the latest quarter end.
Read more
Both totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.Compounded growth
| 10 years | 5 years | 3 years | TTM | |
|---|---|---|---|---|
| Sales growth, compounded | 10.4% | 9.7% | 8.5% | 11.9% |
| Profit growth, compounded | 18.6% | 12.7% | 16.0% | 15.1% |
| Return on equity, average | n/a | 79.6% | 59.5% | 66.0% |
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read more
Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.Questions
What was IDEXX Laboratories' revenue in fiscal 2025?
IDEXX Laboratories (IDXX) reported revenue of $4.3 billion for fiscal 2025, the year ended 31 December 2025, up 10.4% on the year before.
How much did IDEXX Laboratories earn in fiscal 2025?
Net income was $1.1 billion for fiscal 2025, and diluted earnings per share $13.08.
What is IDEXX Laboratories' P/E ratio?
At the close of 6 November 2026, IDEXX Laboratories traded at 45.6 times its earnings over the twelve months to 30 September 2026.
What is IDEXX Laboratories' market cap?
The market cap of IDEXX Laboratories was $53.3 billion at the close of 6 November 2026.
How much debt does IDEXX Laboratories have?
At 30 September 2026 IDEXX Laboratories carried $849 million of debt and $198 million of cash.
Peers: Pharmaceutical Products
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited TAK * | $66.4 billion | n/a | -2.1% | 0.1% | -1.7% | 0.66 | 3.1% |
| argenx SE ARGX * | $57.4 billion | 47.43 | 17.6% | n/a | 89.9% | 0.00 | n/a |
| IDEXX Laboratories Inc. IDXX | $53.3 billion | 45.58 | 63.2% | 32.3% | 11.9% | 0.45 | n/a |
| Teva Pharmaceutical Industries Ltd. TEVA | $49.7 billion | 99.09 | 6.4% | 8.3% | 2.7% | 2.10 | n/a |
| Royalty Pharma plc RPRX | $37.5 billion | 44.27 | 6.9% | 57.1% | 11.4% | 0.88 | 1.4% |
| Biogen Inc. BIIB | $36.7 billion | 106.20 | 1.8% | 4.3% | 2.3% | 0.41 | n/a |
| Lantheus Holdings, Inc. LNTH | $6.6 billion | 24.78 | 19.9% | 18.6% | 2.4% | 0.42 | n/a |
| Neogen Corp. NEOG | $2.6 billion | n/a | -2.7% | -0.8% | -0.3% | 0.37 | n/a |
| Celldex Therapeutics, Inc. CLDX | $2.3 billion | n/a | -47.6% | -213,033.8% | -94.0% | 0.00 | n/a |
| Intellia Therapeutics, Inc. NTLA | $1.6 billion | n/a | -69.5% | -821.2% | -8.1% | 0.12 | n/a |
| QuidelOrtho Corp. QDEL | $732 million | n/a | -20.6% | -4.9% | -4.5% | 1.64 | n/a |
| Myriad Genetics Inc. MYGN | $565 million | n/a | -48.0% | -14.3% | -2.6% | 0.45 | n/a |
All 175 in Pharmaceutical Products
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Eli Lilly & Co. LLY | $1.27 trillion | 43.98 | 68.5% | n/a | 45.5% | 1.23 | 0.5% |
| Johnson & Johnson JNJ | $665.0 billion | 41.86 | 19.7% | n/a | 7.8% | 0.55 | 1.9% |
| AbbVie Inc. ABBV | $514.8 billion | 50.13 | n/a | 32.2% | 10.7% | n/a | 2.4% |
| Merck & Co., Inc. MRK | $361.8 billion | 151.29 | 5.5% | n/a | 4.9% | 1.20 | 2.3% |
| Novartis AG NVS * | $310.3 billion | 22.75 | 30.3% | n/a | 8.4% | 0.62 | 2.5% |
| AstraZeneca PLC AZN * | $289.1 billion | 28.51 | 21.0% | 23.4% | 8.6% | 0.57 | 1.7% |
| Amgen Inc. AMGN | $249.0 billion | 26.70 | 65.4% | 32.4% | 8.2% | 3.76 | 2.2% |
| Gilead Sciences, Inc. GILD | $207.1 billion | n/a | -29.6% | -7.6% | 6.5% | 2.01 | 1.9% |
| Abbott Laboratories ABT | $190.5 billion | 41.03 | 9.2% | 13.8% | 10.0% | 0.61 | 2.3% |
| Novo Nordisk A/S NVO * | $179.9 billion | 11.71 | 52.8% | 41.3% | 6.4% | 0.67 | 4.4% |
| Pfizer Inc. PFE | $167.5 billion | 41.98 | 4.5% | n/a | 1.3% | 0.70 | 5.9% |
| Vertex Pharmaceuticals Inc. VRTX | $138.7 billion | 35.19 | 19.0% | 33.2% | 10.5% | 0.22 | n/a |
| Bristol-Myers Squibb Co. BMY | $127.0 billion | 13.78 | 39.5% | 22.6% | 4.2% | 1.83 | 4.1% |
| Sanofi SNY * | $114.7 billion | 13.22 | 10.9% | n/a | 6.2% | 0.26 | 4.7% |
| Moderna, Inc. MRNA | $102.7 billion | n/a | -40.8% | -116.0% | 13.1% | 0.52 | n/a |
| GSK plc GSK * | $101.0 billion | 13.53 | 34.9% | 24.3% | 4.1% | 1.08 | 3.4% |
| Regeneron Pharmaceuticals, Inc. REGN | $95.5 billion | 19.97 | 14.4% | 28.8% | 18.6% | 0.06 | 0.4% |
| Takeda Pharmaceutical Company Limited TAK * | $66.4 billion | n/a | -2.1% | 0.1% | -1.7% | 0.66 | 3.1% |
| argenx SE ARGX * | $57.4 billion | 47.43 | 17.6% | n/a | 89.9% | 0.00 | n/a |
| IDEXX Laboratories Inc. IDXX | $53.3 billion | 45.58 | 63.2% | 32.3% | 11.9% | 0.45 | n/a |
| Teva Pharmaceutical Industries Ltd. TEVA | $49.7 billion | 99.09 | 6.4% | 8.3% | 2.7% | 2.10 | n/a |
| Royalty Pharma plc RPRX | $37.5 billion | 44.27 | 6.9% | 57.1% | 11.4% | 0.88 | 1.4% |
| Biogen Inc. BIIB | $36.7 billion | 106.20 | 1.8% | 4.3% | 2.3% | 0.41 | n/a |
| Genmab A/S GMAB * | $34.5 billion | 34.89 | 16.5% | 28.6% | 19.2% | 0.90 | n/a |
| Zoetis Inc. ZTS | $32.4 billion | 13.51 | 75.3% | n/a | 1.0% | 2.74 | 2.6% |
| Roivant Sciences Ltd. ROIV | $28.1 billion | n/a | -6.3% | -7,914.8% | -67.6% | 0.00 | n/a |
| Insmed Inc. INSM | $25.1 billion | n/a | -83.4% | -37.1% | 240.0% | 0.76 | n/a |
| United Therapeutics Corp. UTHR | $23.8 billion | 21.21 | 19.6% | 41.4% | 1.9% | 0.00 | n/a |
| Viatris Inc. VTRS | $22.8 billion | n/a | -4.4% | -0.0% | 4.3% | 0.97 | 2.4% |
| BioNTech SE BNTX * | $22.0 billion | n/a | -5.9% | -49.0% | 4.3% | 0.01 | n/a |
| Alnylam Pharmaceuticals, Inc. ALNY | $20.9 billion | 8.10 | 75.6% | 19.5% | 56.2% | 0.28 | n/a |
| Exelixis, Inc. EXEL | $17.0 billion | 20.83 | 48.3% | 40.2% | 9.1% | 0.00 | n/a |
| Neurocrine Biosciences Inc. NBIX | $16.7 billion | 24.43 | 18.1% | 24.0% | 38.0% | 0.00 | n/a |
| Jazz Pharmaceuticals plc JAZZ | $15.1 billion | 79.82 | 4.9% | 9.0% | 13.5% | 1.33 | n/a |
| Kiniksa Pharmaceuticals International, plc KNSA | $14.7 billion | 72.16 | 15.4% | 13.8% | 58.2% | 0.00 | n/a |
| BridgeBio Pharma, Inc. BBIO | $14.6 billion | n/a | n/a | -38.5% | 167.3% | n/a | n/a |
| Elanco Animal Health Inc. ELAN | $12.9 billion | n/a | -2.2% | n/a | 12.1% | 0.52 | n/a |
| Dr. Reddy’s Laboratories Limited RDY * | $12.4 billion | 27.51 | 11.4% | 15.0% | 3.2% | 0.21 | 0.6% |
| Halozyme Therapeutics, Inc. HALO | $11.8 billion | 26.38 | n/a | 37.4% | 45.0% | n/a | n/a |
| Bio-Techne Corp. TECH | $11.4 billion | 66.78 | 7.9% | 19.6% | 0.9% | 0.09 | 0.4% |
| Kymera Therapeutics, Inc. KYMR | $11.2 billion | n/a | -21.6% | -396.0% | 133.8% | 0.00 | n/a |
| Biomarin Pharmaceutical Inc. BMRN | $10.8 billion | n/a | -0.3% | 3.1% | 18.1% | 0.67 | n/a |
| Repligen Corp. RGEN | $9.8 billion | n/a | -0.6% | 2.3% | 13.8% | 0.27 | n/a |
| Madrigal Pharmaceuticals, Inc. MDGL | $9.3 billion | n/a | -24.8% | -10.7% | 92.8% | 0.54 | n/a |
| TG Therapeutics, Inc. TGTX | $9.2 billion | 21.82 | 73.1% | 17.1% | 76.1% | 1.23 | n/a |
| ImmunityBio, Inc. IBRX | $9.1 billion | n/a | n/a | -151.9% | 192.9% | n/a | n/a |
| Krystal Biotech, Inc. KRYS | $8.9 billion | 40.82 | 15.7% | 48.4% | 26.0% | 0.00 | n/a |
| Protagonist Therapeutics, Inc. PTGX | $8.6 billion | 27.97 | 31.5% | 58.6% | 163.7% | 0.00 | n/a |
| Arrowhead Pharmaceuticals, Inc. ARWR | $8.2 billion | n/a | -68.7% | -33.8% | 16.8% | 1.86 | n/a |
| Corcept Therapeutics Inc. CORT | $8.0 billion | 57.24 | 19.5% | 11.5% | 30.0% | 0.00 | n/a |
| Rhythm Pharmaceuticals, Inc. RYTM | $7.8 billion | n/a | -220.3% | -66.7% | 61.0% | 1.17 | n/a |
| Alkermes plc. ALKS | $7.7 billion | n/a | -0.0% | 3.7% | 15.3% | 0.81 | n/a |
| Twist Bioscience Corp. TWST | $7.6 billion | n/a | -30.7% | -33.6% | 19.2% | 0.03 | n/a |
| Cytokinetics Inc. CYTK | $7.5 billion | n/a | n/a | -625.2% | 29.9% | n/a | n/a |
| Axsome Therapeutics, Inc. AXSM | $7.0 billion | n/a | -149.2% | -17.5% | 54.2% | 1.78 | n/a |
| CG Oncology, Inc. CGON | $6.8 billion | n/a | -24.0% | -4,293.5% | 183.6% | 0.00 | n/a |
| Lantheus Holdings, Inc. LNTH | $6.6 billion | 24.78 | 19.9% | 18.6% | 2.4% | 0.42 | n/a |
| Ionis Pharmaceuticals Inc. IONS | $6.5 billion | n/a | -128.5% | -68.0% | -7.4% | 3.01 | n/a |
| Amneal Pharmaceuticals, Inc. AMRX | $6.4 billion | 41.10 | 476.5% | 14.6% | 9.3% | 80.86 | n/a |
| Ligand Pharmaceuticals Inc. LGND | $6.1 billion | 136.65 | 5.4% | 9.5% | 1.0% | 1.17 | n/a |
| Mirum Pharmaceuticals, Inc. MIRM | $6.1 billion | n/a | n/a | -133.6% | 42.2% | n/a | n/a |
| Scholar Rock Holding Corp. SRRK | $5.7 billion | n/a | n/a | n/a | n/a | 0.77 | n/a |
| PTC Therapeutics, Inc. PTCT | $5.5 billion | n/a | n/a | 12.8% | -35.1% | n/a | n/a |
| Crispr Therapeutics AG CRSP | $4.9 billion | n/a | -27.7% | -2,114.8% | -34.3% | 0.36 | n/a |
| Gossamer Bio, Inc. GOSS | $4.8 billion | n/a | n/a | -311.7% | 32.4% | n/a | n/a |
| Travere Therapeutics, Inc. TVTX | $4.7 billion | n/a | -538.0% | -20.5% | 49.4% | 26.72 | n/a |
| Adaptive Biotechnologies Corp. ADPT | $4.5 billion | n/a | -40.0% | -16.2% | 17.9% | 1.90 | n/a |
| Relay Therapeutics, Inc. RLAY | $4.1 billion | n/a | -35.9% | -3,094.9% | 23.9% | 0.00 | n/a |
| Liquidia Corp. LQDA | $4.0 billion | 32.39 | 71.0% | 37.4% | 2,233.6% | n/a | n/a |
| Xenon Pharmaceuticals Inc. XENE | $3.8 billion | n/a | -32.9% | n/a | n/a | 0.00 | n/a |
| Iovance Biotherapeutics, Inc. IOVA | $3.7 billion | n/a | -27.1% | -60.8% | 51.3% | 0.00 | n/a |
| Acadia Pharmaceuticals Inc. ACAD | $3.7 billion | 10.06 | 26.1% | 10.2% | 14.8% | 0.00 | n/a |
| AbCellera Biologics Inc. ABCL | $3.6 billion | n/a | -18.4% | -340.2% | 101.3% | 0.00 | n/a |
| Organon & Co. OGN | $3.6 billion | 18.22 | 17.9% | n/a | -3.2% | 7.17 | 0.6% |
| Tango Therapeutics, Inc. TNGX | $3.6 billion | n/a | -12.1% | -253.4% | 121.5% | 0.00 | n/a |
| Viking Therapeutics, Inc. VKTX | $3.4 billion | n/a | -106.6% | n/a | n/a | 0.43 | n/a |
| Tarsus Pharmaceuticals, Inc. TARS | $3.4 billion | n/a | -675.0% | -102.0% | 86.3% | 0.70 | 0.0% |
| Supernus, Inc. INDV | $3.3 billion | 7.88 | n/a | 40.6% | 16.4% | n/a | n/a |
| DBV Technologies S.A. DBVT | $3.3 billion | n/a | -139.5% | -5,420.1% | -31.5% | 0.00 | n/a |
| Viridian Therapeutics, Inc. VRDN | $3.2 billion | n/a | -78.1% | -1,781.4% | -62.8% | 0.63 | n/a |
| Arcutis Biotherapeutics, Inc. ARQT | $3.2 billion | 121.64 | 12.3% | 6.9% | 60.0% | 0.45 | n/a |
| Denali Therapeutics Inc. DNLI | $3.2 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Supernus, Inc. SUPN | $3.1 billion | 9.62 | n/a | 45.5% | 16.2% | n/a | n/a |
| Bausch Health Companies Inc. BHC | $3.1 billion | n/a | n/a | 11.2% | 10.8% | n/a | n/a |
| Ideaya Biosciences, Inc. IDYA | $3.0 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Adma Biologics, Inc. ADMA | $2.8 billion | 16.52 | 41.6% | 46.5% | 6.3% | 0.45 | n/a |
| Silence Therapeutics plc SLN | $2.8 billion | n/a | -155.8% | -11,106.8% | -97.7% | 0.00 | n/a |
| Vericel Corp. VCEL | $2.8 billion | 85.29 | 8.7% | 8.3% | 25.3% | 0.00 | n/a |
| Xeris Biopharma Holdings, Inc. XERS | $2.8 billion | n/a | -13.3% | 12.7% | 38.4% | 3.89 | n/a |
| Beam Therapeutics Inc. BEAM | $2.7 billion | n/a | -11.2% | -267.7% | 163.3% | 0.11 | n/a |
| Xencor Inc. XNCR | $2.7 billion | n/a | -21.0% | -72.7% | 33.5% | 0.17 | n/a |
| Neogen Corp. NEOG | $2.6 billion | n/a | -2.7% | -0.8% | -0.3% | 0.37 | n/a |
| Celldex Therapeutics, Inc. CLDX | $2.3 billion | n/a | -47.6% | -213,033.8% | -94.0% | 0.00 | n/a |
| Arcus Biosciences, Inc. RCUS | $2.3 billion | n/a | -126.5% | -475.0% | -58.3% | 0.28 | n/a |
| NewAmsterdam Pharma Co. N.V. NAMS | $2.3 billion | n/a | -32.5% | -900.1% | -26.4% | 0.00 | n/a |
| Schrodinger, Inc. SDGR | $2.2 billion | n/a | -19.6% | -49.6% | 4.8% | 0.00 | n/a |
| Septerna, Inc. SEPN | $2.2 billion | n/a | -6.3% | -44.0% | 13,520.1% | 0.00 | n/a |
| Aurinia Pharmaceuticals Inc. AUPH | $2.2 billion | 7.19 | 47.8% | 48.6% | 21.0% | 0.00 | n/a |
| Perrigo Co. plc PRGO | $2.2 billion | n/a | -72.5% | -39.4% | -4.5% | 1.35 | 7.3% |
| Immunome Inc. IMNM | $2.1 billion | n/a | -48.4% | n/a | n/a | 0.00 | n/a |
| Zymeworks Inc. ZYME | $2.1 billion | n/a | -186.6% | -419.0% | -69.8% | 0.00 | n/a |
| Vir Biotechnology, Inc. VIR | $2.1 billion | n/a | -20.6% | -69.8% | 1,696.0% | 0.00 | n/a |
| Prestige Consumer Healthcare Inc. PBH | $2.0 billion | 13.26 | 8.0% | 25.0% | 5.1% | 1.07 | n/a |
| Recursion Pharmaceuticals, Inc. RXRX | $2.0 billion | n/a | -52.5% | -725.4% | 56.2% | 0.01 | n/a |
| Trulieve Cannabis Corp. TRLV | $2.0 billion | n/a | -57.8% | -25.6% | -9.1% | 0.37 | n/a |
| Biocryst Pharmaceuticals Inc. BCRX | $2.0 billion | n/a | n/a | -30.1% | 60.3% | n/a | n/a |
| Harmony Biosciences Holdings, Inc. HRMY | $1.9 billion | 10.96 | 16.7% | 22.2% | 19.8% | 0.14 | n/a |
| Zenas BioPharma, Inc. ZBIO | $1.9 billion | n/a | n/a | n/a | n/a | 1.41 | n/a |
| Sarepta Therapeutics, Inc. SRPT | $1.9 billion | n/a | -7.5% | -2.5% | -18.9% | 0.56 | n/a |
| Maze Therapeutics, Inc. MAZE | $1.9 billion | n/a | n/a | n/a | n/a | 0.09 | n/a |
| Novavax Inc. NVAX | $1.8 billion | n/a | n/a | -21.2% | -61.3% | n/a | n/a |
| Agios Pharmaceuticals, Inc. AGIO | $1.8 billion | n/a | -38.1% | -297.7% | 214.4% | 0.00 | n/a |
| Stoke Therapeutics, Inc. STOK | $1.7 billion | n/a | -69.0% | -913.1% | -86.3% | 0.00 | n/a |
| Generate Biomedicines, Inc. GENB | $1.7 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Nurix Therapeutics, Inc. NRIX | $1.7 billion | 6.61 | 30.5% | 41.3% | 738.8% | 0.00 | 0.0% |
| Eton Pharmaceuticals, Inc. ETON | $1.6 billion | 37.13 | 57.4% | 28.8% | 100.6% | 0.27 | n/a |
| Immunocore Holdings plc IMCR | $1.6 billion | n/a | -7.7% | -6.8% | 13.1% | 0.94 | 0.0% |
| Precigen, Inc. PGEN | $1.6 billion | 128.06 | 29.1% | 21.4% | n/a | 1.12 | n/a |
| Intellia Therapeutics, Inc. NTLA | $1.6 billion | n/a | -69.5% | -821.2% | -8.1% | 0.12 | n/a |
| Ultragenyx Pharmaceutical Inc. RARE | $1.6 billion | n/a | n/a | -64.0% | 15.8% | n/a | n/a |
| uniQure N.V. QURE | $1.5 billion | n/a | -79.0% | -1,001.7% | 28.0% | 0.17 | n/a |
| ANI Pharmaceuticals Inc. ANIP | $1.5 billion | 13.28 | 18.3% | 16.0% | 25.9% | 0.95 | n/a |
| Pacira BioSciences, Inc. PCRX | $1.5 billion | 39.17 | 5.3% | 4.8% | 3.7% | 0.41 | n/a |
| Ocular Therapeutix, Inc. OCUL | $1.4 billion | n/a | -58.0% | -603.0% | -8.1% | 0.14 | n/a |
| Nuvation Bio Inc. NUVB | $1.4 billion | n/a | -59.6% | -61.2% | 654.2% | 1.25 | n/a |
| Korsana Biosciences, Inc. KRSA | $1.4 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Taysha Gene Therapies, Inc. TSHA | $1.4 billion | n/a | -38.6% | -2,792.3% | -32.3% | 0.13 | n/a |
| Innoviva, Inc. INVA | $1.4 billion | 9.60 | 17.0% | 38.8% | 12.8% | 0.23 | n/a |
| Phibro Animal Health Corp. PAHC | $1.3 billion | 13.18 | 24.6% | 12.5% | 10.1% | 1.76 | 1.5% |
| Cronos Group Inc. CRON | $1.3 billion | 21.29 | 5.4% | 3.4% | 55.8% | 0.00 | n/a |
| Avalyn Pharma Inc. AVLN | $1.3 billion | n/a | n/a | n/a | n/a | 0.04 | n/a |
| Opko Health, Inc. OPK | $1.3 billion | n/a | -13.3% | -25.5% | -21.9% | 0.43 | n/a |
| Mannkind Corp. MNKD | $1.3 billion | n/a | n/a | -2.9% | 31.7% | n/a | n/a |
| Inhibrx Biosciences, Inc. INBX | $1.2 billion | n/a | n/a | n/a | n/a | n/a | n/a |
| Omeros Corp. OMER | $1.2 billion | n/a | n/a | n/a | n/a | n/a | n/a |
| Amphastar Pharmaceuticals, Inc. AMPH | $1.2 billion | 13.01 | 12.1% | 18.7% | 3.1% | 0.75 | n/a |
| UroGen Pharma Ltd. URGN | $1.2 billion | n/a | n/a | -12.4% | 159.3% | n/a | n/a |
| Rapport Therapeutics, Inc. RAPP | $1.2 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Janux Therapeutics, Inc. JANX | $1.1 billion | n/a | -11.0% | -599.3% | 132.9% | 0.00 | n/a |
| Harrow, Inc. HROW | $1.0 billion | n/a | -244.9% | -1.0% | 21.1% | 19.24 | n/a |
| Cryoport, Inc. CYRX | $969 million | n/a | -7.8% | -20.0% | 1.1% | 0.39 | n/a |
| Odyssey Therapeutics, Inc. ODTX | $921 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Monte Rosa Therapeutics, Inc. GLUE | $901 million | n/a | -26.4% | -214.5% | -61.3% | 0.00 | n/a |
| Syndax Pharmaceuticals Inc. SNDX | $857 million | n/a | n/a | -61.7% | 159.5% | n/a | n/a |
| MeiraGTx Holdings plc MGTX | $847 million | 12.66 | 36.6% | 46.3% | 948.3% | 0.46 | n/a |
| Aktis Oncology, Inc. AKTS | $847 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Verastem, Inc. VSTM | $794 million | n/a | n/a | n/a | n/a | 11.82 | n/a |
| Lexicon Pharmaceuticals, Inc. LXRX | $791 million | n/a | -38.1% | -147.4% | -45.6% | 0.32 | n/a |
| Nektar Therapeutics NKTR | $759 million | n/a | -17.4% | -257.8% | -27.2% | 0.00 | n/a |
| Collegium Pharmaceutical, Inc. COLL | $752 million | 24.20 | 12.9% | 15.2% | 7.7% | 3.65 | n/a |
| Rigel Pharmaceuticals Inc. RIGL | $746 million | 2.55 | 69.0% | 26.3% | 2.2% | 0.02 | n/a |
| QuidelOrtho Corp. QDEL | $732 million | n/a | -20.6% | -4.9% | -4.5% | 1.64 | n/a |
| Ironwood Pharmaceuticals Inc. IRWD | $728 million | 4.89 | n/a | 62.9% | 18.1% | n/a | n/a |
| Ardelyx, Inc. ARDX | $722 million | n/a | -33.8% | -7.7% | 17.6% | 1.54 | n/a |
| Arbutus Biopharma Corp. ABUS | $721 million | 4.62 | 59.2% | 82.0% | 1,078.8% | 0.00 | n/a |
| Ginkgo Bioworks Holdings, Inc. DNA | $718 million | n/a | -69.2% | -259.9% | -51.5% | 0.00 | n/a |
| Zevra Therapeutics, Inc. ZVRA | $690 million | 9.60 | 32.7% | 60.8% | 75.1% | 0.00 | n/a |
| Wave Life Sciences, Inc. WVE | $665 million | n/a | -52.4% | -320.9% | n/a | 0.00 | n/a |
| Design Therapeutics, Inc. DSGN | $651 million | n/a | -36.6% | n/a | n/a | 0.00 | n/a |
| Kura Oncology, Inc. KURA | $645 million | n/a | -612.8% | -411.9% | n/a | 0.20 | n/a |
| Geron Corp. GERN | $636 million | n/a | n/a | n/a | n/a | 0.53 | n/a |
| Aclaris Therapeutics, Inc. ACRS | $588 million | n/a | -47.7% | -1,414.0% | -59.3% | 0.00 | n/a |
| Myriad Genetics Inc. MYGN | $565 million | n/a | -48.0% | -14.3% | -2.6% | 0.45 | n/a |
| Gyre Therapeutics, Inc. GYRE | $510 million | n/a | -37.5% | -20.6% | 13.5% | 0.00 | n/a |
| Monopar Therapeutics MNPR | $479 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| CytomX Therapeutics, Inc. CTMX | $476 million | n/a | -30.0% | -676.5% | -87.7% | 0.00 | n/a |
| Aquestive Therapeutics, Inc. AQST | $454 million | n/a | n/a | -114.1% | 12.5% | n/a | n/a |
| Evolus, Inc. EOLS | $450 million | n/a | n/a | -4.8% | 13.9% | n/a | n/a |
| Phathom Pharmaceuticals, Inc. PHAT | $425 million | n/a | n/a | -9.3% | 86.8% | n/a | n/a |
| Puma Biotechnology, Inc. PBYI | $421 million | 15.85 | 19.3% | 13.2% | -2.9% | 0.00 | n/a |
| Arvinas, Inc. ARVN | $419 million | n/a | -1.8% | -12.1% | -11.8% | 0.00 | n/a |
| CorMedix Inc. CRMD | $412 million | 2.48 | 40.6% | 47.0% | n/a | 0.00 | n/a |
| Crescent Biopharma, Inc. CBIO | $374 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Canopy Growth Corp. CGC | $276 million | n/a | n/a | -54.2% | 10.7% | 0.38 | n/a |
| Atrium Therapeutics, Inc. RNA | $143 million | n/a | n/a | n/a | n/a | n/a | n/a |
6 companies share its SEC industry code (In Vitro & In Vivo Diagnostic Substances); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read more
By market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.The public record on IDXX
| Dividends | no dividend in its filings for fiscal 2008 onward |
| Filings | 18 in twelve months: 9 current reports (8-K), about 4 results of operations; 3 officer or director change; 1 charter or bylaw amendment, or fiscal year change; 1 shareholder vote; 1 regulation FD disclosure |
| Planned insider sales | 12 Form 144 notices in twelve months, $58.7 million; latest 4 November 2026 |
| Options tape | put/call 0.88 by open interest at the 6 November 2026 close; the straddle prices a 5.1% move to 20 November 2026 |
| 13F holders | 1,311 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc. |
| Insider trading | 57 sales and 0 purchases on Form 4 in twelve months |
| Congress | 0 House trades disclosed in six months |
| Short interest | 1.9 million shares short, 3.62 days to cover at 15 October 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked |
Filings
| Filing | Period | Filed | Where |
|---|---|---|---|
| 10-Q | 30 September 2026 | 2 November 2026 | EDGAR |
| 10-Q | 30 June 2026 | 4 August 2026 | EDGAR |
| 10-Q | 31 March 2026 | 5 May 2026 | EDGAR |
| 10-K | 31 December 2025 | 20 February 2026 | EDGAR |
| 10-Q | 30 September 2025 | 3 November 2025 | EDGAR |
| 10-Q | 30 June 2025 | 4 August 2025 | EDGAR |
| 10-Q | 31 March 2025 | 1 May 2025 | EDGAR |
| 10-K | 31 December 2024 | 21 February 2025 | EDGAR |
| 10-Q | 30 September 2024 | 31 October 2024 | EDGAR |
| 10-Q | 30 June 2024 | 6 August 2024 | EDGAR |
Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.